China News Service, June 17 (Xinhua, China) reported that the US Department of Health said on the 16th that the Trump administration plans to reduce the scope of vaccines funded by research and development, reducing the current 14 kinds to 7 kinds.
On May 27th, local time, the sign that a mask is required for entering the store was posted on the door of a store in the United States.
US government officials also said they expected that once the new coronary pneumonia vaccine began to be distributed (probably in January 2020), many Americans would get it for free.
An American government official, who asked not to be named, said: "We will provide free of charge to any American who is susceptible to infection, can't afford the vaccine and wants to get the vaccine."
The Trump administration launched Operation "Curve" in May, a joint project between the US Department of Health and the Department of Defense, aimed at accelerating the development of a new crown vaccine. Government officials say this effort maximizes the "possibility" of developing vaccines by the end of 2020.
The US government previously announced that it has invested more than US$2 billion to support three vaccines in research and development, one of which is experimentally developed by AstraZeneca and Oxford University, one is provided by Modena, and the other is developed by Johnson & Johnson. The government also provided Merck and Sanofi with more than US$30 million each for their own vaccine work.
A government official said that the US government will consider which companies it will ultimately support based on the success of the trial and manufacturing capabilities.
In addition, the New York Times reported earlier in June that the White House had selected five companies to produce vaccines, namely Modena, AstraZeneca, Pfizer, Johnson & Johnson and Merck.